Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the ASPIRATION registry

医学 经皮冠状动脉介入治疗 阿司匹林 传统PCI 内科学 氯吡格雷 危险系数 人口 心脏病学 急性冠脉综合征 倾向得分匹配 置信区间 心肌梗塞 环境卫生
作者
Chunfeng Dai,Muyin Liu,Zheng Yang,Youran Li,You Zhou,Danbo Lu,Ying Xia,Ao Chen,Chenguang Li,Hao Lu,Yuxiang Dai,Jianying Ma,Zhangwei Chen,Juying Qian,Junbo Ge
出处
期刊:BMC Medicine [BioMed Central]
卷期号:22 (1) 被引量:3
标识
DOI:10.1186/s12916-024-03374-3
摘要

Abstract Background Indobufen is widely used in patients with aspirin intolerance in East Asia. The OPTION trial launched by our cardiac center examined the performance of indobufen based dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). However, the vast majority of patients with acute coronary syndrome (ACS) and aspirin intolerance were excluded. We aimed to explore this question in a real-world population. Methods Patients enrolled in the ASPIRATION registry were grouped according to the DAPT strategy that they received after PCI. The primary endpoints were major adverse cardiovascular and cerebrovascular events (MACCE) and Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding. Propensity score matching (PSM) was adopted for confounder adjustment. Results A total of 7135 patients were reviewed. After one-year follow-up, the indobufen group was associated with the same risk of MACCE versus the aspirin group after PSM (6.5% vs. 6.5%, hazard ratio [HR] = 0.99, 95% confidence interval [CI] = 0.65 to 1.52, P = 0.978). However, BARC type 2, 3, or 5 bleeding was significantly reduced (3.0% vs. 11.9%, HR = 0.24, 95% CI = 0.15 to 0.40, P < 0.001). These results were generally consistent across different subgroups including aspirin intolerance, except that indobufen appeared to increase the risk of MACCE in patients with ACS. Conclusions Indobufen shared the same risk of MACCE but a lower risk of bleeding after PCI versus aspirin from a real-world perspective. Due to the observational nature of the current analysis, future studies are still warranted to further evaluate the efficacy of indobufen based DAPT, especially in patients with ACS. Trial registration Chinese Clinical Trial Register ( https://www.chictr.org.cn ); Number: ChiCTR2300067274.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
失眠的安卉完成签到,获得积分10
刚刚
JingP完成签到,获得积分10
1秒前
怡然的乘风完成签到 ,获得积分10
1秒前
1秒前
2秒前
4秒前
小心薛了你完成签到,获得积分10
4秒前
5秒前
CHEN完成签到 ,获得积分10
7秒前
乘舟江行完成签到,获得积分10
7秒前
幽默鱼完成签到,获得积分10
8秒前
鱼女士完成签到,获得积分10
8秒前
开放如天发布了新的文献求助10
9秒前
HuLL完成签到 ,获得积分10
10秒前
金甲狮王完成签到,获得积分10
10秒前
11秒前
王者归来完成签到,获得积分10
12秒前
周游完成签到,获得积分10
12秒前
Yang22完成签到,获得积分10
13秒前
14秒前
韶似狮发布了新的文献求助10
14秒前
如意烨霖完成签到,获得积分10
14秒前
有终完成签到 ,获得积分10
15秒前
gYang完成签到,获得积分10
15秒前
粒子耶完成签到,获得积分10
15秒前
ntxlks完成签到,获得积分10
16秒前
纯真含灵发布了新的文献求助30
16秒前
风趣的梦露完成签到 ,获得积分10
17秒前
开放如天完成签到,获得积分10
19秒前
深情安青应助perway采纳,获得10
19秒前
19秒前
动力小滋完成签到,获得积分10
21秒前
22秒前
繁荣的代秋完成签到,获得积分10
22秒前
认真丹亦完成签到 ,获得积分10
22秒前
LZY完成签到,获得积分10
22秒前
大气的雁桃完成签到,获得积分10
22秒前
花草般的清香完成签到,获得积分10
22秒前
糖糖糖唐完成签到,获得积分10
23秒前
无花果应助合适的梦菡采纳,获得10
23秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968578
求助须知:如何正确求助?哪些是违规求助? 3513406
关于积分的说明 11167631
捐赠科研通 3248853
什么是DOI,文献DOI怎么找? 1794499
邀请新用户注册赠送积分活动 875150
科研通“疑难数据库(出版商)”最低求助积分说明 804671